Form 4 for BIIB Biogen
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001127602-24-004794 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-13 | 2024-02-09 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $240.98 | -445 | 8,636 | -5% | -$107.2K |
| D | 2024-02-13 | 2024-02-09 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +1,515 | 9,081 | +20% | $0 |
| D | 2024-02-13 | 2024-02-09 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | -1,515 | 1,515 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | F | D | 445 | $240.98 | 8,636 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-09 | M | A | 1,515 | $0.00 | 9,081 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-02-09 | M | D | 1,515 | $0.00 | 1,515 | D | $0.00 · — to 2025-02-10 | 1,515 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. |